Is there a role for systemic corticosteroids in the management of stable chronic obstructive pulmonary disease?

American Journal of Respiratory Medicine

Volumn 2, Issue 6, 2003, Pages 451-458

  Wood Baker, Richard ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYTOKINE; PLACEBO; PREDNISOLONE; PROTEINASE; PROTEINASE INHIBITOR; TOBACCO SMOKE;

ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATARACT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; EXERCISE; FORCED EXPIRATORY VOLUME; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INFECTION; INHIBITION KINETICS; LUNG ALVEOLUS; LUNG FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; NEUTROPHIL CHEMOTAXIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; RISK ASSESSMENT; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME;

EID: 0346264738     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256672     Document Type: Article

References (61)

1. Oxman A, Cook D, Guyatt G. Users' guides to the medical literature: VI. How to use and overview. JAMA 1994: 272 (17): 1367-71
2. Cook D, Guyatt G, Laupacis A, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102 (4): 305S-11S
3. Stanbrook M, Kaplan A, Juurlink D, et al. Systemic corticosteroids for stable chronic obstructive pulmonary disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration: issue 3. Oxford: Update Software, 2001
4. Greenhalgh T. How to read a paper. 2nd ed. London: BMJ Books, 2001
5. Celli B, Snider G, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995: 152: S77-S120
6. Stanescu D, Sanna A, Veriter C, et al. Identification of smokers susceptible to development of' chronic airflow limitation: a 13-year follow-up. Chest 1998; 114: 416-25
7. Aubry M-C, Wright J, Myers J. The pathology of smoking-related lung diseases. Clin Chest Med 2000; 21 (1): 11-35
8. Shapiro S. Evolving concepts in the pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med 2000; 21 (4): 621-32
9. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumour necrosis factor-alpha in induced aputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153 (2): 530-4
10. Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000: 106 (9): 1081-93
11. Falkenstein E, Tillmann H-C, Christ M, et al. Multiple actions of steroid hormones: a focus on rapid, nongenomic effects. Pharmacol Rev 2000; 52: 513-55
12. Falkenstein E, Norman A, Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab 2000; 85: 2072-5
13. Sackett D, Straus S, Richardson W, et al. Evidence-based medicine: how to practice and teach EBM. 2nd ed. London: Harcourt Publishers Ltd, 2000
14. Moyes E, Kershaw R. Long-continued treatment with tetracycline and prednisolone in chronic bronchitis: a controlled trial. Lancet 1957; 11: 1187-91
15. O'Reilly J, Shaylor J, Fromings K, et al. The use of the 12 minute walking test in assessing the effect of oral steroid therapy in patients with chronic airways obstruction. Br J Dis Chest 1982; 76: 374-82
16. Eliasson O, Hoffman J, Trueb D, et al. Corticosteroids in chronic obstructive pulmonary disease: a clinical trial and reassessment of the literature. Chest 1986; 89: 484-90
17. Mitchell D, Gildeh P, Dimond A, et al. Value of serial peak expiratory flow measurements in assessing treatment response in chronic airflow limitation. Thorax 1986; 41: 606-10
18. Brightling C, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356: 1480-5
19. Lukas D. Some effects of adrenocorticotropic hormone and cortisone on pulmonary function of patients with obstructive emphysema. Am Rev Tuberc 1951; 64: 279-94
20. Kennedy M, Comb B. Cortisone in pneumoconiosis with and without reversible bronchoconstriction. Lancet 1954; I: 77-9
21. Bickerman H, Beck G, Barach A. The use of prednisone (Meticorten) in respiratory disease: 2. Pulmonary emphysema and pulmonary fibrosis. J Chronic Dis 1955; 2: 247-59
22. Franklin W, Michelson A, Lowell F, et al. Bronchodilators and corticosteroids in the treatment of obstructive pulmonary emphysema. N Engl J Med 1958; 258: 774-8
23. Lorriman G. The effects of bronchodilators on pulmonary ventilation and diffusion in asthma and emphysema. Thorax 1959; 14: 146-52
24. Ogilvie A, Newell D. A maintenance trial of combined steroid and antibiotic treatment in a series of asthmatics with chronic bronchitis. Br J Dis Chest 1960; 54: 308-20
25. Cullen J, Reidt W. A study of the respiratory effects of prednisone in diffuse airway obstruction. Am Rev Respir Dis 1960: 82: 508-15
26. Clifton M, Stuart-Harris C. Steroid therapy in chronic bronchitis. Lancet 1962; I: 1311-3
27. Beerel F, Hershel J, Tyler J. A controlled study of the effect of prednisone on airflow obstruction in severe pulmonary emphysema. N Engl J Med 1963; 268: 226-30
28. Freedman B. Bronchodilators and corticosteroids in chronic bronchitis and emphysema. BMJ 1963; 5371: 1509-12
29. Pecora L, Zoss L, Baum G, et al. A study of the physiologic effects of intravenous methylprednisolone in chronic pulmonary emphysema. Am Rev Respir Dis 1963; 89: 528-32
30. Morgan W, Rusche E. A controlled trial of the effects of steroids in obstructive airway disease. Thorax 1964; 39: 924-7
31. Fuleihan F, Feisal K, Malouf N. Effect of corticosteroids on pulmonary function in chronic bronchitis with airway obstruction. Am Rev Respir Dis 1967; 96: 678-84
32. Klein R, Salvaggio J, Kurdur V. The response of patients with "idiopathic" obstructive pulmonary disease and "allergic" obstructive bronchitis to prednisone. Ann Intern Med 1969; 71: 711-8
33. Petty R, Brink G, Miller M, et al. Objective functional improvement in chronic bronchitis. Lancet 1970; II: 552-7
34. Harding S, Freedman S. A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response. Thorax 1978; 33: 214-8
35. Shim C, Stover D, Williams M. Response to corticosteroids in chronic bronchitis. J Allergy Clin Immunol 1978; 62 (6): 363-7
36. Mendella L, Manfreda J, Warren C, et al. Steroid response in stable chronic obstructive pulmonary disease. Ann Intern Med 1982; 96: 17-21
37. Blair G, Light R. Treatment of chronic obstructive pulmonary disease with corticosteroids. Chest 1984; 86: 524-8
38. Strain D, Kinasewitz G, Franco D, et al. Effect of steroid therapy on exercise performance in patients with irreversible chronic obstructive pulmonary disease. Chest 1985; 88: 718-21
39. Grove A, Lipworth B, Ingram C, et al. A comparison of the effects of prednisolone and mianserin on ventilatory, exercise and psychometric parameters in patients with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1995; 48: 13-8
40. Sahn S. Corticosteroids in chronic bronchitis and pulmonary emphysema. Chest 1978; 73 (3): 389-96
41. Callahan C, Dittus R, Katz B. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. Ann Intern Med 1991; 114 (3): 216-23
42. Easterbrook P, Berlin J, Gopalan R, et al. Publication bias in clinical research. Lancet 1991; 337: 867-72
43. Hudson LD, Monti CM. Rationale and use of corticosteroids in chronic obstructive pulmonary disease. Med Clin North Am 1990; 74 (3): 661-90
44. Renkema TE, Schouten JP, Koeter GH, et al. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109 (5): 1156-62
45. Davies L, Nisar M, Pearson M, et al. Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease. QJM 1999; 92: 395-400
46. Paggiaro P, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-80
47. Pauwels R, Lofdahl C, Laitinen L, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53
48. Burge P, Calverley P, Jones P, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303
49. Pizzichini E, Pizzichini M, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511-7
50. Chanez P, Vignola A, O'Shaugnessy T. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-34
51. Axelrod L. Glucocorticoid therapy. Medicine 1976; 55: 39-65
52. Schlaghecke R, Kornely E, Santen R, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotrophin-releasing hormone. N Engl J Med 1992; 326: 226-30
53. McEvoy C, Niewoehner D. Adverse effects of corticosteroid therapy for COPD. Chest 1997; 111 (3): 732-43
54. Reid I. Osteoporosis: emerging consensus. Aust N Z J Med 1997; 27: 643-7
55. Cowan S, Morin S, Ernst P. Bisphophonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases. Thorax 1998; 53: 331-2
56. Corticosteroid-induced osteoporosis. Drug Ther Bull 1996; 11: 84-6
57. Smith B, Phillips P, Heller R. Asthma and chronic obstructive airway diseases are associated with osteoporosis and fractures: a literature review. Respirology 1999; 4: 101-9
58. Sin D, Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-4
59. Schols A, Wesseling G, Kester A, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337-42
60. Rice K, Rubins J, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randoinized trial. J Respir Crit Care Med 2000; 162 (1): 174-8
61. Wood-Baker R, Walters EH. The role of corticosteroids in acute exacerbations of chronic obstructive pulmonary disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 1998